Enzalutamide Suppliers & Bulk Manufacturers
Available Forms: Tablet & Capsule
Available Strengths: Capsules- 40 mg, Tablet - 40 mg & 80 mg
Reference Brands: Xtandi® (EU & US)
Category:
Oncology Cancer Care
Enzalutamide is an oral androgen receptor inhibitor used in treating advanced prostate cancer, available in 40 mg capsules and 40/80 mg tablets in the US and EU under the brand name Xtandi®..
Enzalutamide is available in Tablet & Capsule
and strengths such as Capsules- 40 mg, Tablet - 40 mg & 80 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Enzalutamide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Enzalutamide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Enzalutamide is a next-generation androgen receptor inhibitor indicated for the treatment of prostate cancer, including metastatic castration-resistant and non-metastatic castration-resistant forms. Marketed as Xtandi®, it is available in 40 mg capsules and 40 mg/80 mg tablets in both the US and EU. It works by blocking androgen signaling pathways, helping slow disease progression. With proven clinical benefits and oral administration, Enzalutamide represents a high-value B2B oncology opportunity for pharmaceutical partners targeting the oncology segment in regulated markets such as the EU and United States.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing